Why Haven't We Cured Cancer?

2024-10-31

[public] 48.3K views, 8.69K likes, dislikes audio only

To learn more about Florida International University's research, visit https://FIU.edu

A person’s genes alone don’t tell us enough about how to most effectively treat their cancer.

LEARN MORE

**************

To learn more about this topic, start your googling with these keywords:

- Precision Medicine: A medical model that tailors specific drugs to specific patients based on genetic profiling.

- Functional Precision Medicine: A medical model that involves directly treating live tumor cells with drugs to gain information about a patient's tumor.

- HER2-positive cancer: A type of cancer caused by a specific excess growth factor protein that has been shown to be treatable by specific medications.

SUPPORT MINUTEEARTH

**************************

If you like what we do, you can help us!:

- Become our patron: https://patreon.com/MinuteEarth

- Our merch: http://dftba.com/minuteearth

- Our book: https://minuteearth.com/books

- Sign up to our newsletter: http://news.minuteearth.com

- Share this video with your friends and family

- Leave us a comment (we read them!)

CREDITS

*********

David Goldenberg | Script Writer, Narrator and Director

Arcadi Garcia i Rius | Storyboard Artist

Sarah Berman | Illustration, Video Editing and Animation

Nathaniel Schroeder | Music

MinuteEarth is produced by Neptune Studios LLC

https://neptunestudios.info

OUR STAFF

************

Lizah van der Aart • Sarah Berman • Cameron Duke

Arcadi Garcia i Rius • David Goldenberg • Melissa Hayes

Alex Reich • Henry Reich • Peter Reich

Ever Salazar • Leonardo Souza • Kate Yoshida

OUR LINKS

************

Youtube | https://youtube.com/MinuteEarth

TikTok | https://tiktok.com/@minuteearth

Twitter | https://twitter.com/MinuteEarth

Instagram | https://instagram.com/minute_earth

Facebook | https://facebook.com/Minuteearth

Website | https://minuteearth.com

Apple Podcasts| https://podcasts.apple.com/us/podcast/minuteearth/id649211176

REFERENCES

**************

Acanda De La Rocha, A.M., Berlow, N.E., Fader, M. et al. Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers. Nat Med 30, 990–1000 (2024). https://doi.org/10.1038/s41591-024-02848-4

Acanda De La Rocha, Arlet. (2024) Personal communication. Researcher at The Azzam Lab at FIU. https://stempel.fiu.edu/research/labs/cancer-research/

Lee Schwartzberg et al., Precision Oncology: Who, How, What, When, and When Not?. Am Soc Clin Oncol Educ Book 37, 160-169(2017). https://doi.org/10.1200/EDBK_174176

Anthony Letai, Patrick Bhola, Alana L. Welm (2022). Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations, Cancer Cell, Volume 40, Issue 1, Pages 26-35, ISSN 1535-6108. https://doi.org/10.1016/j.ccell.2021.12.004.

Letai A. Functional Precision Medicine: Putting Drugs on Patient Cancer Cells and Seeing What Happens. Cancer Discov. 2022 Feb;12(2):290-292. doi: 10.1158/2159-8290.CD-21-1498. PMID: 35140175; PMCID: PMC8852353.

Rulten, Stuart L., Richard P. Grose, Susanne A. Gatz, J. Louise Jones, and Angus J. M. Cameron. 2023. "The Future of Precision Oncology" International Journal of Molecular Sciences 24, no. 16: 12613. https://doi.org/10.3390/ijms241612613

Tomasik, B., Garbicz, F., Braun, M., Bieńkowski, M., & Jassem, J. (2024). Heterogeneity in precision oncology. Cambridge Prisms: Precision Medicine, 2, e2. https://doi.org/10.1017/pcm.2023.23

Szabo, L. (2018). Are We Being Misled About Precision Medicine? New York Times. https://www.nytimes.com/2018/09/11/opinion/cancer-genetic-testing-precision-medicine.html

Kornauth, C., et al. (2022). Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. Cancer discovery, 12(2), 372–387. https://doi.org/10.1158/2159-8290.CD-21-0538

Malani, D., et al (2022). Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer discovery, 12(2), 388–401. https://doi.org/10.1158/2159-8290.CD-21-0410